Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $1,279,818.54 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Huda Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regeneron Pharmaceuticals Stock Up 1.6%

Regeneron Pharmaceuticals stock opened at $784.28 on Thursday. The firm has a market capitalization of $82.91 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 2.07 and a beta of 0.40. The company’s 50 day simple moving average is $770.88 and its 200 day simple moving average is $678.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business posted $12.07 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. WPG Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $29,000. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Kemnay Advisory Services Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Evercore increased their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Oppenheimer reiterated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Finally, Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $793.81.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approved Dupixent for allergic fungal rhinosinusitis (AFRS) in patients aged 6+, marking the drug’s ninth U.S. indication and addressing a hard-to-treat sinus disease; approval is supported by Phase 3 data showing symptom reduction and lower need for steroids or repeat surgery, boosting Dupixent’s long-term revenue potential. GlobeNewswire: Dupixent approved for AFRS
• Positive Sentiment: Regeneron and Sanofi announced the same FDA approval in commercial/press coverage highlighting strong Phase 3 data and broader market adoption potential for Dupixent across sino-nasal and type 2 inflammatory diseases. Yahoo: Dupixent AFRS coverage
• Positive Sentiment: The FDA accepted Regeneron’s BLA for garetosmab under Priority Review for fibrodysplasia ossificans progressiva (FOP), accelerating the regulatory timeline for a potential new orphan indication and adding near-term pipeline value if approved. Yahoo: FDA accepts garetosmab BLA
• Positive Sentiment: Analyst and media bullish takes (e.g., The Motley Fool) highlight Regeneron’s product depth, manufacturing capabilities and combined commercial strength with Sanofi as reasons the stock could outperform long-term — supportive commentary that can sustain investor interest after the approval news. Fool: Reasons REGN could outperform
• Neutral Sentiment: Market commentary is flagging short-term price cooling and a valuation reassessment despite recent gains; investors are revisiting multiples and growth assumptions after mixed short-term returns. Yahoo: Valuation assessment
• Neutral Sentiment: Recent MarketBeat coverage notes a modest dividend increase and a range of analyst target revisions — supportive but incremental to valuation — with consensus still in the moderate-buy area. MarketBeat: Analyst notes & dividend
• Negative Sentiment: Regeneron director Huda Zoghbi sold 1,638 shares (~49% reduction of her holding) in a disclosed transaction; while insider sales are common and may be for personal reasons, large disclosed sales can create short-term selling pressure or raise governance questions for some investors. American Banking News: Insider sale

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.